WallStreetZenWallStreetZen

NYSE: PBH
Prestige Consumer Healthcare Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for PBH

Based on 1 analyst offering 12 month price targets for Prestige Consumer Healthcare Inc

Min Forecast
$72.00+37.75%
Avg Forecast
$72.00+37.75%
Max Forecast
$72.00+37.75%

Should I buy or sell PBH stock?

Based on 2 analysts offering ratings for Prestige Consumer Healthcare Inc.

Buy
Strong Buy
1 analysts 50%
Buy
0 analysts 0%
Hold
1 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although PBH's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates PBH as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their PBH stock forecasts and price targets.

PBH stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-15
lockedlocked$00.00+00.00%2026-05-14

1 of 1

Forecast return on equity

Is PBH forecast to generate an efficient return?

Company
13.08%
Industry
51.15%
Market
169.95%
PBH's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PBH forecast to generate an efficient return on assets?

Company
5.49%
Industry
18.71%
PBH is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PBH earnings per share forecast

What is PBH's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$4.57+27.65%
Avg 2 year Forecast
$4.94+38.01%
Avg 3 year Forecast
$5.29+47.83%
PBH's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

PBH revenue forecast

What is PBH's revenue in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$1.2B+7.79%
Avg 2 year Forecast
$1.3B+14.67%
Avg 3 year Forecast
$1.3B+17.21%
PBH's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

PBH earnings growth forecast

How is PBH forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
13.97%
Industry
15.85%
Market
30.85%
PBH's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
PBH's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
PBH's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

PBH revenue growth forecast

How is PBH forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
5.92%
Industry
8.75%
Market
13.49%
PBH's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PBH's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PBH vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
PBH$52.27$72.00+37.75%Buy
RGC$5.06N/AN/A
BHC$6.21$8.00+28.82%Hold
SUPN$47.87$67.00+39.96%Strong Buy
HCM$12.25$17.00+38.78%Strong Buy
View Top Pharmaceutical Stocks

Prestige Consumer Healthcare Stock Forecast FAQ

Is Prestige Consumer Healthcare Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NYSE: PBH) stock is to Buy PBH stock.

Out of 2 analysts, 1 (50%) are recommending PBH as a Strong Buy, 0 (0%) are recommending PBH as a Buy, 1 (50%) are recommending PBH as a Hold, 0 (0%) are recommending PBH as a Sell, and 0 (0%) are recommending PBH as a Strong Sell.

If you're new to stock investing, here's how to buy Prestige Consumer Healthcare stock.

What is PBH's earnings growth forecast for 2027-2029?

(NYSE: PBH) Prestige Consumer Healthcare's forecast annual earnings growth rate of 13.97% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 15.85%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.85%.

Prestige Consumer Healthcare's earnings in 2026 is $172,012,000.On average, 9 Wall Street analysts forecast PBH's earnings for 2027 to be $216,487,353, with the lowest PBH earnings forecast at $205,207,479, and the highest PBH earnings forecast at $232,300,969. On average, 9 Wall Street analysts forecast PBH's earnings for 2028 to be $234,063,301, with the lowest PBH earnings forecast at $214,957,156, and the highest PBH earnings forecast at $257,172,593.

In 2029, PBH is forecast to generate $250,724,920 in earnings, with the lowest earnings forecast at $236,777,861 and the highest earnings forecast at $267,618,675.

What is PBH's revenue growth forecast for 2027-2029?

(NYSE: PBH) Prestige Consumer Healthcare's forecast annual revenue growth rate of 5.92% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.75%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.49%.

Prestige Consumer Healthcare's revenue in 2026 is $1,104,885,000.On average, 9 Wall Street analysts forecast PBH's revenue for 2027 to be $56,423,055,702, with the lowest PBH revenue forecast at $51,069,734,716, and the highest PBH revenue forecast at $63,860,855,656. On average, 9 Wall Street analysts forecast PBH's revenue for 2028 to be $60,023,519,374, with the lowest PBH revenue forecast at $52,111,974,200, and the highest PBH revenue forecast at $69,403,674,730.

In 2029, PBH is forecast to generate $61,350,005,990 in revenue, with the lowest revenue forecast at $53,201,588,206 and the highest revenue forecast at $70,540,663,258.

What is PBH's forecast return on assets (ROA) for 2027-2029?

(NYSE: PBH) forecast ROA is 5.49%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 18.71%.

What is PBH's Price Target?

According to 1 Wall Street analyst that have issued a 1 year PBH price target, the average PBH price target is $72.00, with the highest PBH stock price forecast at $72.00 and the lowest PBH stock price forecast at $72.00.

The Wall Street analyst predicted that Prestige Consumer Healthcare's share price could reach $72.00 by May 15, 2027. The average Prestige Consumer Healthcare stock price prediction forecasts a potential upside of 37.75% from the current PBH share price of $52.27.

What is PBH's Earnings Per Share (EPS) forecast for 2027-2029?

(NYSE: PBH) Prestige Consumer Healthcare's current Earnings Per Share (EPS) is $3.58. On average, analysts forecast that PBH's EPS will be $4.57 for 2027, with the lowest EPS forecast at $4.33, and the highest EPS forecast at $4.90. On average, analysts forecast that PBH's EPS will be $4.94 for 2028, with the lowest EPS forecast at $4.54, and the highest EPS forecast at $5.43. In 2029, PBH's EPS is forecast to hit $5.29 (min: $5.00, max: $5.65).

What is PBH's forecast return on equity (ROE) for 2027-2029?

(NYSE: PBH) forecast ROE is 13.08%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.